Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx has signed a third agreement with Merck Serono, expanding its partnership to co-discover and co-develop Nanobodies against two targets in osteoarthritis.
Subscribe to our email newsletter
As per the agreement, both the companies will develop multi-specific products with extended half-lives, by exploiting the features of Nanobody.
Ablynx will receive an upfront payment of EUR20m and will take up the charge for all activities and costs for each programme, excluding manufacturing costs and costs relating to certain in vivo models.
In addition, Ablynx is also entitled to receive a further EUR15m for each programme if the pre- clinical packages are accepted by Merck Serono.